OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Cancer is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Untangling the threads of immunotherapy research	649
Enhancing childhood cancer targetability	459
Shooting for multiplexed pathology with Orion	450
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	444
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	367
A low-coverage liquid biopsy for lung cancer	361
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	334
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	296
Breaking frontiers with multidisciplinary cancer research	276
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	273
A macrophage-activated abscopal effect	267
An oncolytic circular RNA therapy	245
Considering molecular alterations as pan-cancer tissue-agnostic targets	225
Gut decisions in CAR T cell therapy	221
PARP11 interfer(on)es with CAR T cell efficacy	205
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	161
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	160
MALAT1 protects dormant tumor cells from immune elimination	157
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	152
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	149
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	140
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	137
The cGAS–STING pathway and cancer	127
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	125
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	125

Beating cancer one carbon at a time	123
DePICting T cell–APC crosstalk in cancer	123
Expanding the options for KRAS inhibition	121
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	118
Palmitate oxidation drives a pro-metastatic post-translational modification	118
Stress granules shape metabolic reprogramming and drug resistance	116
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	112
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	112
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	110
The importance of being generous	102
Bone marrow progenitor-like cells against leukemia cure	99
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	98
Shaping the microenvironment in peritoneal metastases	98
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	97
Impact of context-dependent autophagy states on tumor progression	95
Advancing therapeutics in small-cell lung cancer	95
Determinants of resistance and response to melanoma therapy	95
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	94
Sarcoma ecotypes determine immunotherapy benefit	93
Innate immunity drives epithelial cell plasticity during prostate tumor formation	93
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	92
Antibody avidity meets multiple myeloma	92
Inflammation meets translation in AML	91
Evolving landscape of nasopharyngeal carcinoma therapy	91
Thriving in diverse ecosystems	91
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	90
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	90
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	89
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	88
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	83
Key insights from ESMO Congress 2025	83
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	78
Cycling back to folate metabolism in cancer	78
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	77
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	76
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	76
A comeback for checkpoint inhibition in multiple myeloma	76
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	75
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	74
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	73
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	73
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	73
Radiation sparks a dark side in neutrophils	72
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	72
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	72
Radioligand cancer therapy comes to the fore	72
Multimodal data integration improves immunotherapy response prediction	71
Dual inhibition of EGFR and PI3K with a single drug	71